Aptus Capital Advisors LLC Invests $240,000 in DexCom, Inc. (NASDAQ:DXCM)

Aptus Capital Advisors LLC bought a new stake in DexCom, Inc. (NASDAQ:DXCM) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 3,083 shares of the medical device company’s stock, valued at approximately $240,000.

Other institutional investors also recently added to or reduced their stakes in the company. Private Trust Co. NA grew its stake in shares of DexCom by 266.3% during the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company’s stock worth $26,000 after purchasing an additional 245 shares in the last quarter. Optiver Holding B.V. purchased a new stake in DexCom during the 4th quarter worth about $33,000. TD Private Client Wealth LLC boosted its position in shares of DexCom by 62.8% during the 4th quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company’s stock worth $34,000 after acquiring an additional 167 shares in the last quarter. Larson Financial Group LLC increased its holdings in shares of DexCom by 40.5% in the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company’s stock valued at $37,000 after acquiring an additional 137 shares during the last quarter. Finally, Heck Capital Advisors LLC purchased a new stake in DexCom during the fourth quarter worth approximately $38,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Insiders Place Their Bets

In other DexCom news, CEO Kevin R. Sayer sold 32,498 shares of the stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total transaction of $2,287,209.24. Following the transaction, the chief executive officer now owns 372,029 shares of the company’s stock, valued at $26,183,401.02. This trade represents a 8.03 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Jereme M. Sylvain sold 7,000 shares of the business’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $73.83, for a total transaction of $516,810.00. Following the sale, the executive vice president now directly owns 135,482 shares of the company’s stock, valued at $10,002,636.06. This represents a 4.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 66,926 shares of company stock valued at $4,734,384 in the last quarter. 0.32% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on DXCM shares. Morgan Stanley boosted their price objective on shares of DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a research report on Friday, February 14th. Mizuho started coverage on DexCom in a report on Thursday, April 10th. They set an “outperform” rating and a $85.00 price objective on the stock. Wells Fargo & Company restated an “overweight” rating on shares of DexCom in a research note on Saturday, March 8th. Robert W. Baird reduced their price objective on DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a research note on Friday, May 2nd. Finally, Citigroup raised their target price on shares of DexCom from $101.00 to $104.00 and gave the stock a “buy” rating in a research report on Tuesday, March 4th. Five research analysts have rated the stock with a hold rating, thirteen have given a buy rating and three have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, DexCom currently has an average rating of “Moderate Buy” and a consensus target price of $98.11.

DexCom Trading Up 2.3 %

Shares of DXCM stock opened at $85.29 on Friday. DexCom, Inc. has a fifty-two week low of $57.52 and a fifty-two week high of $132.26. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59. The business has a fifty day simple moving average of $71.03 and a 200-day simple moving average of $77.09. The stock has a market cap of $33.44 billion, a P/E ratio of 59.64, a P/E/G ratio of 2.30 and a beta of 1.43.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, May 1st. The medical device company reported $0.32 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.01). DexCom had a net margin of 14.29% and a return on equity of 30.14%. The company had revenue of $1.04 billion during the quarter, compared to analysts’ expectations of $1.02 billion. During the same period in the previous year, the company posted $0.32 EPS. DexCom’s quarterly revenue was up 12.5% compared to the same quarter last year. On average, analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.